



Universiteit  
Leiden  
The Netherlands

## Next generation lipopeptide antibiotics

Al Ayed, U.K.

### Citation

Al Ayed, U. K. (2024, January 23). *Next generation lipopeptide antibiotics*. Retrieved from <https://hdl.handle.net/1887/3714346>

Version: Publisher's Version

[Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

License: <https://hdl.handle.net/1887/3714346>

**Note:** To cite this publication please use the final published version (if applicable).

## List of publications

**Al Ayed, K.**; Zamarbide Losada, D.; Machushynets, N. V.; Terlouw, B.; Elsayed, S. S.; Schill, J.; Trebosc, V.; Pieren, M.; Medema, M. H.; van Wezel, G. P.; Martin, N. I. Total Synthesis and Structure Assignment of the Relacidine Lipopeptide Antibiotics and Preparation of Analogues with Enhanced Stability. *ACS Infect Dis* **2023**, 9 (4), 739–748. <https://doi.org/10.1021/acsinfecdis.3c00043>.

Ballantine, R. D.; **Al Ayed, K.\***; Bann, S. J.; Hoekstra, M.; Martin, N. I.; Cochrane, S. A. Linearization of the Brevicidine and Laterocidine Lipopeptides Yields Analogs That Retain Full Antibacterial Activity. *J Med Chem* **2023**, 66 (8), 6002–6009. <https://doi.org/10.1021/acs.jmedchem.3c00308>.

Ballantine, R. D.\*; **Al Ayed, K.\***; Bann, S. J.; Hoekstra, M.; Martin, N. I.; Cochrane, S. A. Synthesis and Structure-Activity Relationship Studies of N-Terminal Analogs of the Lipopeptide Antibiotics Brevicidine and Laterocidine. *RSC Med. Chem.* **2022**, 00, 1–3. <https://doi.org/10.1039/D2MD00281G>

**Al Ayed, K.\***; Ballantine, R. D.\*; Hoekstra, M.; Bann, S. J.; Wesseling, C. M. J.; Bakker, A. T.; Zhong, Z.; Li, Y.-X.; Brüchle, N. C.; Van Der Stelt, M.; Cochrane, S. A.; Martin, N. I. Synthetic Studies with the Brevicidine and Laterocidine Lipopeptide Antibiotics Including Analogs with Enhanced Properties and in Vivo Efficacy. *Chem. Sci.* **2022**, 13 (12), 3563–3570. <https://doi.org/10.1039/D2SC00143H>

Zhou, J.\*; Mock, E. D.\*; **Al Ayed, K.**; Di, X.; Kantae, V.; Burggraaff, L.; Stevens, A. F.; Martella, A.; Mohr, F.; Jiang, M.; Van Der Wel, T.; Wendel, T. J.; Ofman, T. P.; Tran, Y.; De Koster, N.; Van Westen, G. J. P.; Hankemeier, T.; Van Der Stelt, M. Structure-Activity Relationship Studies of  $\alpha$ -Ketoamides as Inhibitors of the Phospholipase A and Acyltransferase Enzyme Family. *J. Med. Chem.* **2020**, 63 (17), 9340–9359. <https://doi.org/10.1021/acs.jmedchem.0c00522>

Zhou, J.; Mock, E. D.; Martella, A.; Kantae, V.; Di, X.; Burggraaff, L.; Baggelaar, M. P.; **Al-Ayed, K.**; Bakker, A.; Florea, B. I.; Grimm, S. H.; Den Dulk, H.; Li, C. T.; Mulder, L.; Overkleef, H. S.; Hankemeier, T.; Van Westen, G. J. P.; Van Der Stelt, M. Activity-Based Protein Profiling Identifies  $\alpha$ -Ketoamides as Inhibitors for Phospholipase A2 Group XVI. *ACS Chem. Biol.* **2019**, 14 (2), 164–169. <https://doi.org/10.1021/acscchembio.8b00969>

de Bruin, G.; Huber, E. M.; Xin, B.-T.; van Rooden, E. J.; **Al-Ayed, K.**; Kim, K.-B.; Kisseelev, A. F.; Driessens, C.; van der Stelt, M.; van der Marel, G. A.; Groll, M.; Overkleef, H. S. Structure-Based Design of B1i or B5i Specific Inhibitors of Human Immunoproteasomes. *J. Med. Chem.* **2014**, 57 (14), 6197–6209. <https://doi.org/10.1021/jm500716s>

\*Authors contributed equally

## Curriculum Vitae

Karol Al Ayed was born on 5 July 1990 in Gdynia, Poland. In 2000 he moved to the Netherlands with his mother. After graduating high school at the Stanislas college in Delft, he started the bachelor life science & technology at Leiden University and TU Delft. During the bachelor program Karol became increasingly more interested in chemistry which led him to pursue an internship in the group of prof.dr. Hermen Overkleeft. There he worked on the synthesis and evaluation of selective immunoproteasome inhibitors. The work there sparked Karol's curiosity in chemistry even further and led him to pursue a master's degree in chemistry at Leiden University. During this time he worked on the discovery of novel phospholipase A/acyltransferase inhibitors in the group of prof.dr. Mario van der Stelt. After obtaining the degree of master in science in chemistry Karol pursued a PhD in the group of prof.dr. Nathaniel Martin, initially at Utrecht University and subsequently at Leiden University. There he mainly worked on the synthesis and assessment of lipopeptide antibiotics. As of February 2023, Karol is working as a Lead Scientist at the Nuclear Research and Consultancy Group (NRG) in Petten.